A recent study further revealed that SETD2 deficiency in renal tissues alters the metabolic microenvironment by affecting glycolysis, lipid metabolism, and sphingomyelin biosynthesis, thereby contributing to the development of clear cell renal cell carcinoma [9]. This evidence concerns the gene SETD2 and clear cell renal carcinoma.